Ximelagatran: recent trial results
This article has no abstract so we have provided the first paragraph of the full text.
Ximelagatran, a prodrug form of melagatran, is an oral direct thrombin inhibitor that promises to overcome some of the problems associated with other anticoagulants such as warfarin. Two papers published in JAMA now report on recent clinical trials of the drug. In the first study, Fiessinger et al. investigate the use of ximelagatran for the prevention of recurrent venous thromboembolism, whereas the second paper describes its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
